Curtis Cooper profile picture

Contact Information

Curtis Cooper, MD, FRCPC
613-737-8899 ext72296

ORCID logo

Curtis Cooper

Scientist, Clinical Epidemiology Program
Ottawa Hospital Research Institute
Director, Ottawa Hospital and Regional Hepatitis Program
The Ottawa Hospital
Assoicate Professor, Dept of Medicine
University of Ottawa

Research Interests

Brief Biography

Dr. Curtis Cooper trained at the University of Saskatchewan (MD 1994). He received certification in Internal Medicine in 1997 and in Infectious Diseases in 1999 while at the University of Manitoba. He completed an HIV Research Fellowship and Masters of Epidemiology in 2002 while at the University of Ottawa. He is currently an Associate Professor with the University of Ottawa, Infectious Diseases Consultant with the Ottawa Hospital Division of Infectious Diseases, Associate Clinical Researcher with the Ottawa Health Research Institute and Director of the Ottawa Hospital and Regional Viral Hepatitis Program. As a clinical researcher, his research activities encompass HIV, viral hepatitis, and vaccine development. His work is focused on the development of new therapeutic agents and the delivery of treatment that maximizes safety, adherence and safety.

Selected Publications

Assal A, Mackie D, Cooper C. Transient elastography, APRI, and ultrasound have minimal utility in chronic low-replicative hepatitis B infection. Eur J Gastroenterol Hepatol. 2014 Sep;26(9):1010-4.

Yam KK, Gipson E, Klein M, Walmsley S, Haase D, Halperin S, Scheifele D, Ward BJ, Cooper C. High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine. J Clin Immunol. 2014 May 14.

Hull M, Klein M, Shafran S, Tseng A, Giguère P, Côté P, Poliquin M, Cooper C. CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coninfection in adults. Can J Infect Dis Med Microbiol 2013;24(4)-217-238.

Cooper C, Shafran S, Greenbloom S, Enns R, Farley J, Hilzenrat N, Williams K, Elkashab M, Abadir N, Neuman M. Single-dose infliximab in hepatitis C genotype 1-naive patients with high serum tumour necrosis factor-alpha does not influence efficacy of pegylated interferon alpha-2b/ribavirin therapy. Can J Gastroenterol. 2013 Nov 8.

Al-Omari A, Cowan J, Turner L, Cooper C. Antidepressant prophylaxis reduces depression risk but does not improve sustained virological response in hepatitis C interferon recipients without depression at baseline: A systemic review and meta-analysis. Can J Gastroenterol. 2013 Oct;27(10):575-581.

Diseases, conditions and populations of interest

Research and clinical approaches